Live Stock Coverage: What’s Propelling Second Sight Medical Products Inc to Decline So Much?

Live Stock Coverage: What's Propelling Second Sight Medical Products Inc to Decline So Much?

The stock of Second Sight Medical Products Inc (NASDAQ:EYES) is a huge mover today! About 134,732 shares traded hands. Second Sight Medical Products Inc (NASDAQ:EYES) has declined 53.70% since April 18, 2016 and is downtrending. It has underperformed by 58.13% the S&P500.
The move comes after 8 months negative chart setup for the $110.68 million company. It was reported on Nov, 18 by Barchart.com. We have $2.10 PT which if reached, will make NASDAQ:EYES worth $11.07 million less.

According to Zacks Investment Research, “Second Sight Medical Products, Inc. is a medical device company. It develops, manufactures, and markets implantable prosthetic devices to restore some functional vision to blind patients. The Company provides Argus II system, an implantable neurostimulation device for the treatment of outer retinal degenerations, such as retinitis pigmentosa. Second Sight Medical Products, Inc. is headquartered in Sylmar, California.”

Another recent and important Second Sight Medical Products Inc (NASDAQ:EYES) news was published by Businesswire.com which published an article titled: “Second Sight Medical Products, Inc. Announces Completion of Oversubscribed …” on June 01, 2016.

EYES Company Profile

Second Sight Medical Products, Inc., incorporated on May 22, 2003, is engaged in developing, manufacturing and marketing prosthetic devices that restore vision to blind individuals. The Company’s product, the Argus II System, treats outer retinal degenerations, such as retinitis pigmentosa (RP). The Argus II System provides an artificial form of vision that differs from the vision of people with normal sight. It does not restore normal vision and it does not slow or reverse the progression of the disease.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Tags: , ,

Leave a Comment